EP Patent

EP4491622A3 — Cardiac sarcomere inhibitors

Assigned to Cytokinetics Inc · Expires 2025-04-30 · 1y expired

What this patent protects

Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R 1 , R 2 , R 3 , G 1 , G 2 ,and G 3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a ph…

USPTO Abstract

Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R 1 , R 2 , R 3 , G 1 , G 2 ,and G 3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP4491622A3
Jurisdiction
EP
Classification
—
Expires
2025-04-30
Drug substance claim
No
Drug product claim
No
Assignee
Cytokinetics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.